MARKETWIRE.NET

Decode Your Next Market Move

Preparing Your Business in a Post Pandemic World! The New Study on Induced Pluripotent Stem Cell (iPSC) Provides Answers to Key Strategic Questions You Might Have

The global market for Induced Pluripotent Stem Cell ((iPSC) is projected to reach US$1.8 billion by 2025, driven by the growing value of stem cells in medicine.

Global Industry Analysts, Inc. (GIA) launches comprehensive analysis of industry segments, market trends, growth drivers, market share, size and demand forecasts on the global Induced Pluripotent Stem Cell (iPSC) market. Report segmentation includes Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells, Other Cell Types); Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering, Other Research Methods); Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine, Other Applications) ).

10 June 9:05 A.M., California/Marketwire/ - According to the new market research report, the global market for Induced Pluripotent Stem Cell ((iPSC) is projected to reach US$1.8 billion by 2025, driven by the growing value of stem cells in medicine. Stem Cell research is an exciting field where continuous discoveries are being made on new sources of stem cells and new methods of their acquisition and harvesting. Of late, adult stem cells have garnered a lion's share of the stem cell space, purely based on the fact that they require less expensive clinical trials, need to comply with fewer regulatory norms and ethical issues compared to other stem cell variants such as embryonic stem cells. Researchers around the world have been focusing research activities to develop adult stem cell therapies in order to combat a variety of diseases ranging from diabetes to heart disease. Factually, adult stem cells are the only stem cells that have been approved for use in transplants for the treatment of diseases such as cancer. Interestingly, with drug development based on embryonic stem cells being challenged amid growing debate over ethics and regulation of this research, iPSCs offers an alternate step forward in the commercialization of stem cell therapies and regenerative medicine. Embryonic stem cell research continues to remain embroiled in ethical, religious, and political controversies across various countries around the world.

Induced Pluripotent Stem Cells (iPSs), which are reprogrammed to mimic embryonic stem cell-like state allowing expression of genes and human cells needed for therapeutic purposes, offers an attractive alternate way forwarding in furthering the goals of stem cell research. Pioneered in 2006 and developed in the following year, these cells are created by conversion of somatic cells into PSCs by introducing certain genes including Myc, Klf4, Oct3/4 and Sox2. Pluripotent stem cells hold tremendous potential in the regenerative medicine arena. Based on their ability to proliferate indefinitely and develop into desirable cell type such as heart, liver, neuronal and pancreatic cells, iPSCs offer a source of new cells that can replace lost or damaged cells. For instance, iPSCs can be developed into beta islet cells, blood cells or neuronal cells for the treatment of diabetes, leukemia and neurological disorders, respectively. Parkinson's, Alzheimer's & spinal cord injuries are key neurologic diseases expected to benefit from iPS research. Dramatic rise in cancer cases worldwide and the need for novel anti-cancer therapies will emerge as a key driver for the growth of iPSCs. Interest in cancer research soars high on new hopes of direct reprogramming of cancer cells with enforced expression of pluripotency factors and the resulting dedifferentiation of transformed cancer cells.

Key Competitors Covered in the Report
Axol Bioscience Ltd.
Cynata Therapeutics Limited
Evotec SE
Fate Therapeutics, Inc.
FUJIFILM Cellular Dynamics, Inc.
Ncardia
Pluricell Biotech
REPROCELL USA, Inc.
Shenzhen Sanqi Biotechnology Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Takara Bio, Inc.
Thermo Fisher Scientific, Inc.
ViaCyte, Inc.

Geographies Analyzed in the Report
USA
Canada
Japan
China
Europe (France, Germany, Italy, UK, Rest of Europe)
Asia-Pacific
Rest of World

More details

Research Methodology
This latest edition of the research study is conducted and published by Global Industry Analysts, Inc., in close collaboration with senior executives in the industry driving strategy, business development, marketing, sales, product management, technology and operations. All analysis and findings published in the report are based on validated engagements from a total executive pool size of 1737. Among this pool, 313 direct interactions with domain experts were carried out via our proprietary market research platform, MarketGlass. Among the 69 unique participations, a total of 31 validated responses were received as part of this report's primary research outreach program. We are unique in the industry to provide our clients with the validated list executive engagements and the complete project data stack.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) (www.strategyr.com) is the world's only influencer driven AI powered market research company. Serving more than 41,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for 33 years, offering the widest coverage of topics, geographic markets, competitive brands, and companies profiled.

Contact Us:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
Email: sales@StrategyR.com